Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient

• DOI: 10.3855/jidc.13081
• Publication Date: 2020-11-10T21:41:08Z
• Authors: Jianxin Tao; Yunjuan Nie; Hui Wu; Liang Cheng; Yuanwang Qiu; Juanjuan Fu; Xiufeng Jiang
• Keywords: Renal replacement therapy

Introduction: The coronavirus disease 2019 (COVID-19) pandemic is spreading rapidly. Critically ill cases of COVID-19 can rapidly progress to acute respiratory distress syndrome and multiple organ failures. However, no effective drugs have been available till now, leading more than 300,000 deaths up 29 April 2020. Here, we present a critically case utilizing umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs).
 Case presentation: A 72-year-old man was admitted, with the diagnosis COVID-19, ARDS, type-2 diabetes, diabetic nephropathy, renal insufficiency, hypertension. His clinical condition continually developed be life-threatening even receiving various treatment options including antiviral therapy extracorporeal membrane oxygenation. Between 28 February 8 March 2020, patient given 5-time intravenous infusions UCB-MSCs. hematological biochemical indexes, lymphocytes function improved. Pulmonary static compliance increased significantly PaO2/FiO2 ratio maintained stable. On 10, he received lung transplantation.
 Conclusions: Our current findings suggested that UCB-MSCs may show some positive effect in treating critical extent, for its delaying deterioration efficacy function, though limited.